Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study
UST and VDZ were effective and well tolerated even when used as second-line or subsequent therapies for VEO-IBD.
Authors
- Naoya Tsumura (ORCID: https://orcid.org/0000-0002-0793-2121)
- Yugo Takaki (ORCID: https://orcid.org/0000-0002-3191-0192)
- Yuri Etani (ORCID: https://orcid.org/0000-0003-3005-4707)
- Ryo Ebana (ORCID: https://orcid.org/0000-0002-1276-736X)
- M Usami (ORCID: https://orcid.org/0000-0001-8206-1285)
- T Ishige
- Ryusuke Nambu (ORCID: https://orcid.org/0000-0002-7206-7111)
- Hiroki Fujikawa (ORCID: https://orcid.org/0000-0002-4297-9881)
- Shingo Kurasawa
- Tatsuki Mizuochi (ORCID: https://orcid.org/0000-0002-2943-7068)
- Koji Yokoyama (ORCID: https://orcid.org/0000-0003-1504-6151)
- Yusuke Hoshi
- Itaru Iwama
- Fumihiko Kakuta
- Emiri Kaji
- M. Masashi Yoshida
- Shin-ichiro Hagiwara
- Ichiro Takeuchi
- Takahiro Kudo
- Atsushi Yoden
- Katsuhiro Arai
- Takuya Nishizawa
- Hirotaka Shimizu
- Hideki Kumagai
Institutions
- Kanazawa University (JP)
- Kurume University (JP)
- Hiroshima University (JP)
- Shinshu University (JP)
- Jichi Medical University (JP)
- Kanazawa Medical University (JP)
- Gunma University (JP)
- Juntendo University (JP)
- Miyagi Children's Hospital (JP)
- Osaka Women's and Children's Hospital (JP)
- Saitama Children's Medical Center (JP)
- Japanese Red Cross Kumamoto Hospital (JP)
- Okinawa Prefectural Chubu Hospital (JP)
- National Center For Child Health and Development (JP)
- Toyo Institute of Food Technology (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Journal of Gastroenterology
- Published
- 2026-01-03
- DOI
- https://doi.org/10.1007/s00535-025-02334-9
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00